You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Iris Shapira Yalon resigned from XTL Biopharmaceuticals Ltd.’s Board, effective upon her successor’s shareholder appointment or November 20, 2026, whichever comes first. The Board nominated Gilai Dolev as external director for an initial three-year term, subject to shareholder approval.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XTLB
this stock
Xtl Biopharmaceuticals Ltd
|
$4.18M | — | — | — | 0.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$139.20B | +21.1% | +46.2% | 35.4 | 1.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.29B | +20.6% | +20.8% | 21.0 | 2.1% |
|
MRNA
Moderna, Inc.
|
$91.20B | +776.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$67.38B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Iris Shapira Yalon resigned from XTL Biopharmaceuticals Ltd.’s Board, effective upon her successor’s shareholder appointment or November 20, 2026, whichever comes first. The Board nominated Gilai Dolev as external director for an initial three-year term, subject to shareholder approval.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XTLB | -15.4% | -14.1% | -40.4% | +5.6% | -26.7% |
| SPY | -0.7% | -1.3% | +2.5% | +1.5% | +12.5% |
| vs SPY | -14.7% | -12.8% | -42.8% | +4.1% | -39.2% |
